Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $4.93 Consensus Price Target from Analysts

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have been assigned an average rating of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $5.67.

SGMO has been the subject of several research reports. Royal Bank of Canada restated a “sector perform” rating and set a $2.00 price target on shares of Sangamo Therapeutics in a report on Thursday, March 14th. HC Wainwright restated a “buy” rating and set a $5.00 price target (up from $3.00) on shares of Sangamo Therapeutics in a report on Tuesday, March 19th. Finally, StockNews.com assumed coverage on shares of Sangamo Therapeutics in a research report on Saturday. They set a “sell” rating on the stock.

Institutional Investors Weigh In On Sangamo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Miracle Mile Advisors LLC acquired a new stake in shares of Sangamo Therapeutics in the 3rd quarter valued at $25,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Sangamo Therapeutics in the 3rd quarter valued at $26,000. Mackenzie Financial Corp boosted its stake in shares of Sangamo Therapeutics by 72.4% in the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 31,003 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Sangamo Therapeutics by 255.2% in the 3rd quarter. SG Americas Securities LLC now owns 88,542 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 63,612 shares in the last quarter. Finally, Golden State Equity Partners raised its holdings in shares of Sangamo Therapeutics by 22.5% in the third quarter. Golden State Equity Partners now owns 166,265 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 30,500 shares during the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Stock Performance

SGMO stock opened at $0.52 on Tuesday. The stock has a market cap of $107.44 million, a P/E ratio of -0.35 and a beta of 1.39. The firm has a 50 day simple moving average of $0.77 and a 200 day simple moving average of $0.59. Sangamo Therapeutics has a 52 week low of $0.29 and a 52 week high of $1.78.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.09). The company had revenue of $2.04 million for the quarter, compared to analyst estimates of $8.96 million. Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. Sell-side analysts predict that Sangamo Therapeutics will post -0.54 EPS for the current year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.